Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost
Background One in three high-risk prostate cancer patients treated with radiotherapy recur.
Detection of lymph node metastasis and microscopic disease spread using conventional …
Detection of lymph node metastasis and microscopic disease spread using conventional …
[HTML][HTML] Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate …
M Miszczyk, Ł Magrowski, T Krzysztofiak… - Radiotherapy and …, 2023 - Elsevier
Background and purpose Despite several prospective trials showing a clinical benefit of
combining external beam radiotherapy (EBRT) with brachytherapy boost (BTB) for the …
combining external beam radiotherapy (EBRT) with brachytherapy boost (BTB) for the …
Differential outcomes of re-stratified high-risk prostate cancer patients treated with external beam radiation therapy plus high-dose-rate brachytherapy boost
D Carignan, B Morales, P Després, W Foster… - Journal of …, 2024 - termedia.pl
Purpose: We report outcomes of high-risk prostate cancer (PCa) patients, initially classified
according to a 3-tier NCCN classification system, treated with external beam radiation …
according to a 3-tier NCCN classification system, treated with external beam radiation …
Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer …
N Andruska, T Agabalogun, BW Fischer-Valuck… - Brachytherapy, 2022 - Elsevier
BACKGROUND Current recommendations regarding radiotherapy treatment for unfavorable
intermediate-risk prostate cancer (UIR-PCa) include external beam radiotherapy (EBRT)± …
intermediate-risk prostate cancer (UIR-PCa) include external beam radiotherapy (EBRT)± …
Biologically Effective Dose (BED) Correlation With Biochemical Control After Low–Dose Rate Prostate Brachytherapy for Clinically Low-Risk Prostate Cancer
EF Miles, JW Nelson, AK Alkaissi, S Das… - International Journal of …, 2010 - Elsevier
PURPOSE: To assess the correlation of postimplant dosimetric quantifiers with biochemical
control of prostate cancer after low–dose rate brachytherapy. METHODS AND MATERIALS …
control of prostate cancer after low–dose rate brachytherapy. METHODS AND MATERIALS …
Significant association of brachytherapy boost with reduced prostate cancer–specific mortality in contemporary patients with localized, unfavorable-risk prostate …
M Xiang, PL Nguyen - Brachytherapy, 2015 - Elsevier
Purpose A randomized trial recently found that adding brachytherapy (BT) boost to external
beam radiation therapy (EBRT) improves biochemical recurrence-free survival but not …
beam radiation therapy (EBRT) improves biochemical recurrence-free survival but not …
[引用][C] The Declining Use of Brachytherapy Boost for Prostate Cancer Despite Associated Survival Advantage
SM Glaser, GK Balasubramani, RM Benoit… - …, 2016 - brachyjournal.com
Purpose Dose-escalated external beam radiotherapy (DE-EBRT) has been demonstrated to
improve outcomes in men with intermediate-high risk prostate cancer. Brachytherapy …
improve outcomes in men with intermediate-high risk prostate cancer. Brachytherapy …
Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk …
VR Dhere, BW Fischer-Valuck, S Goyal, Y Liu… - Brachytherapy, 2021 - Elsevier
PURPOSE Addition of a brachytherapy boost to external beam radiation therapy (EBRT)
reduces prostate cancer (PCa) recurrence at the expense of genitourinary (GU) toxicity …
reduces prostate cancer (PCa) recurrence at the expense of genitourinary (GU) toxicity …
Low-/high-dose-rate brachytherapy boost in patients with intermediate-risk prostate cancer treated with radiotherapy: long-term results from a single institution team …
SR Villalba, PM Denia, MJ Pérez-Calatayud… - Journal of …, 2021 - termedia.pl
Results Median overall follow-up for the total cohort was 66.5 months (range, 16-185
months). There were no significant differences in bPFS, overall survival, cause specific …
months). There were no significant differences in bPFS, overall survival, cause specific …
Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer
V Muralidhar, M Xiang, PF Orio III, NE Martin… - Journal of …, 2016 - termedia.pl
Purpose: Recent retrospective data suggest that brachytherapy (BT) boost may confer a
cancer-specific survival benefit in radiation-managed high-risk prostate cancer. We sought …
cancer-specific survival benefit in radiation-managed high-risk prostate cancer. We sought …
相关搜索
- brachytherapy boost prostate cancer
- brachytherapy boost dose rate
- brachytherapy boost beam radiotherapy
- dose rate prostate cancer
- brachytherapy boost differential outcomes
- brachytherapy boost significant association
- brachytherapy boost declining use
- dose rate differential outcomes
- significant association prostate cancer
- declining use prostate cancer
- biochemical control prostate cancer
- brachytherapy boost survival advantage
- brachytherapy boost distant metastases
- survival advantage prostate cancer
- brachytherapy boost survival outcomes
- brachytherapy boost beam radiation